The Mechanics of Corporate Consolidation and Market Efficiency
When two major corporations announce a merger, the standard public relations narrative often centers on the creation of a more efficient, streamlined entity. The core argument presented to regulators and the public is straightforward: by combining operations, the newly formed company can manufacture, distribute, and market products at a lower cost. In theory, these operational savings are then passed down the supply chain, resulting in lower consumer prices. This efficiency defense is a cornerstone of corporate merger justifications in the UK and across global markets.
However, the actual economic outcomes of corporate consolidation frequently deviate from these theoretical projections. Recent pharmaceutical research conducted by Loughborough University challenges the assumption that operational efficiencies automatically translate into retail savings for shoppers. By examining real-world market data, researchers have demonstrated that the relationship between reduced operational costs and consumer prices is highly complex, often yielding unexpected results that disadvantage the end buyer.
The Standard Argument for Mergers
Proponents of company mergers point to several mechanisms through which savings are generated. Redundant administrative roles can be eliminated, supply chain logistics can be consolidated, and bulk purchasing power can drive down raw material costs. When companies present their cases to competition authorities, they frequently provide projected savings figures—often in the hundreds of millions of pounds—to argue that the merger serves the public interest. The underlying premise is that a reduction in marginal costs will inevitably lead to a reduction in retail prices due to competitive pressures.
The Reality of Post-Merger Market Dynamics
The flaw in the standard argument lies in its oversimplification of market dynamics. While the merged entity may indeed achieve lower costs, the simultaneous reduction in the number of independent competitors fundamentally alters the competitive landscape. With fewer players in the market, the remaining firms face less pressure to undercut one another. As a result, the cost savings are frequently retained as increased profit margins rather than being converted into lower consumer prices.
A Closer Look at the GSK and Pfizer Pharmaceutical Merger
To move beyond theoretical debates, researchers from Loughborough University, alongside partners from the University of East Anglia, the Philippine Competition Commission, the University of the Philippines, and E.CA Economics, conducted an empirical analysis of a high-profile corporate consolidation. The study focused on the 2019 merger of the consumer healthcare divisions of two pharmaceutical giants: GSK and Pfizer. The companies had projected that this combination would eventually generate approximately £500 million in annual savings.
This specific merger provided an ideal subject for pharmaceutical research because it involved well-defined, widely used products—specifically, over-the-counter cough and cold medicines—in a distinct geographic market: the Philippines. By analyzing transactional data before and after the merger, the researchers could directly measure whether the promised efficiencies materialized and, crucially, whether those efficiencies benefited consumers.
Explore our related articles for further reading.
Quantifying the Shift in Costs and Consumer Prices
The empirical findings from the study paint a nuanced picture of post-merger market behavior. The data confirmed that the merger did, in fact, generate measurable efficiencies for a portion of the combined business. Specifically, the estimated cost of supplying the former Pfizer products fell by 9.43%. In line with the traditional merger argument, the retail prices of these specific Pfizer-branded medicines dropped by 6.57%.
However, a broader look at consumer prices across the market revealed a starkly different reality. Rather than experiencing a market-wide decrease in costs, consumers faced price increases from other major brands. The research showed that GSK’s prices increased by an estimated 3.25% following the merger. More strikingly, Sanofi, a major international competitor that was not part of the deal, raised its prices by 8.55%. Only the cheaper, locally manufactured products from Unilab remained broadly unchanged in price.
Why Rival Prices Increase After a Merger
The fact that a non-merged rival like Sanofi significantly raised its prices is a critical insight for understanding modern antitrust economics. In a highly competitive market with multiple independent players, a company that raises its prices risks losing substantial market share to cheaper alternatives. However, when a merger reduces the number of major players, the competitive constraints are loosened. The remaining firms no longer have to worry as much about aggressive price-cutting from the merged entity, allowing them to raise their own prices to capture higher margins.
Understanding Implicit Coordination in Oligopolies
The Loughborough University researchers found evidence consistent with what economists term “coordinated effects.” This concept does not imply that the executives of GSK, Pfizer, and Sanofi sat in a room and explicitly agreed to fix prices. Instead, it describes a market environment where the reduction in competitors makes it significantly easier for firms to anticipate and match each other’s pricing strategies without any direct communication.
How Fewer Competitors Change Pricing Strategies
In a market with many players, pricing strategies are unpredictable, making coordination difficult. When the market consolidates into an oligopoly—dominated by a few large firms—each player can easily observe and react to the others’ pricing moves. The removal of a major competitor through a merger eliminates a “maverick” firm that might have previously disrupted the market by aggressively lowering prices. Without this disruptive force, the remaining firms can implicitly coordinate on higher prices, knowing that their rivals are likely to follow suit rather than initiate a price war.
Share your experiences in the comments below.
Strategic Implications for Competition Authorities
The findings from this study carry significant weight for competition regulators in the UK, the EU, and globally. Historically, regulatory bodies have sometimes accepted efficiency defenses at face value, allowing mergers to proceed based on the promise of lower costs. The Loughborough University research argues that authorities must adopt a more skeptical and comprehensive analytical framework.
Rethinking the Evaluation of Merger Efficiencies
Regulators must move beyond simply asking whether a merger will make a combined company more efficient. Instead, they must evaluate how those efficiencies will interact with the new, less competitive market structure. If a merger is likely to facilitate implicit coordination among the remaining players, the promised cost savings may never reach the consumer. Competition authorities need to employ sophisticated economic modeling to predict coordinated effects, ensuring that the long-term impact on consumer prices is accurately assessed before a deal is approved.
The Role of Academic Institutions in Shaping Policy
Rigorous, data-driven academic research is essential for informing public policy and corporate regulation. Institutions like Loughborough University in the UK play a vital role in bridging the gap between theoretical economics and real-world market outcomes. By publishing detailed analyses of major corporate actions, universities provide regulators, policymakers, and business leaders with the empirical evidence required to make sound decisions. The work of researchers like Professor Farasat Bokhari demonstrates how academic inquiry can directly influence the understanding of complex economic phenomena such as company mergers and consumer prices.
Submit your application today.
Applying These Insights to Global Business Strategy
Beyond regulatory circles, these insights are highly relevant for business strategists and entrepreneurs. Understanding the dynamics of post-merger markets can inform competitive strategy in industries undergoing consolidation.
- For Acquiring Firms: Recognize that cost synergies can be realized without sacrificing pricing power. The market structure post-merger may support higher margins on existing product lines, even as operational costs decrease.
- For Competing Firms: A merger between two rivals often signals an opportunity to increase your own prices. The reduction in market competition provides cover to improve profitability without fear of severe market share loss.
- For Disruptors: Consolidated markets often become complacent, focusing on implicit coordination rather than innovation. This creates a strategic opening for agile, lower-cost competitors to aggressively capture market share by bucking the trend of rising prices.
Schedule a free consultation to learn more.
Conclusion: Balancing Efficiency with Market Competition
The narrative that company mergers automatically benefit consumers through lower prices is not supported by the empirical evidence. As demonstrated by the Loughborough University study of the GSK and Pfizer consumer healthcare merger, operational efficiencies are real, but they do not necessarily dictate retail pricing. When mergers reduce the number of independent competitors, they can trigger implicit coordination, leading to stagnant or even increased consumer prices. For competition authorities, corporate executives, and economists, the primary focus must shift from the mere existence of cost savings to the structural realities of the post-merger marketplace. Only by carefully weighing efficiency gains against the loss of competitive pressure can we ensure that markets continue to serve the interests of the consumer.
